HomeGeneticsConditionSézary syndrome
Back to Condition
Sézary syndrome
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Sézary syndrome

Sézary syndrome is an aggressive and rare form of cutaneous T-cell lymphoma, characterized by cancerous T cells in the blood, skin, and lymph nodes, leading to a severe, itchy rash and other systemic symptoms.

Overview

Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform.

People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss, skin swelling, thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward. Some people with Sézary syndrome are less able to control their body temperature than people without the condition.

The cancerous T cells can spread to other organs in the body, including spleen. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer.

Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments.

Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.

Frequency

Sézary syndrome is a rare condition, although its prevalence is unknown. It is the second most common form of cutaneous T-cell lymphoma after mycosis fungoides, accounting for approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma.

Causes & Risk Factors

The cause of Sézary syndrome is unknown. Most affected individuals have one or more chromosomal abnormalities, such as the loss or gain of genetic material. These abnormalities occur during a person's lifetime and are found only in the DNA of cancerous cells. Abnormalities have been found on most chromosomes, but some regions are more commonly affected than others. People with this condition tend to have losses of DNA from regions of chromosomes 10 and 17 or additions of DNA to regions of chromosomes 8 and 17. It is unclear whether these alterations play a role in Sézary syndrome, although the tendency to acquire chromosomal abnormalities (chromosomal instability) is a feature of many cancers. It can lead to genetic changes that allow cells to grow and divide uncontrollably.

Inheritance

The inheritance pattern of Sézary syndrome has not been determined. This condition occurs in people with no history of the disorder in their family and is not thought to be inherited in most cases.

Other Names

  • Sezary erythroderma
  • Sezary syndrome
  • Sezary's lymphoma

Frequently Asked Questions

Patients have a higher incidence of secondary lymphomas and solid tumors. Regular monitoring with complete blood counts, imaging (CT/MRI) for lymphadenopathy, and periodic dermatologic exams are recommended. Discuss with your oncologist the need for periodic bone marrow evaluation and screening for other malignancies.
Sézary syndrome rash is usually a widespread, red, intensely itchy erythroderma that covers most of the body, often accompanied by swollen lymph nodes, hair loss, or thickened skin on palms and soles. Unlike eczema or psoriasis, the rash does not typically improve with topical steroids and may spread rapidly. A skin biopsy and a blood test for circulating Sézary cells (flow cytometry) are needed for confirmation.
Diagnosis requires a combination of a skin biopsy showing atypical T cells, a peripheral blood smear or flow cytometry revealing >1,000 Sézary cells per microliter, and immunophenotyping (CD4+, CD7- T cells). PCR for T‑cell receptor gene rearrangement can also support clonality.
Systemic options include retinoids (bexarotene), interferon‑α, histone deacetylase inhibitors (romidepsin), and monoclonal antibodies (mogamulizumab). These act on circulating malignant T cells, whereas skin‑directed treatments (topical steroids, phototherapy) mainly control local skin lesions but do not reduce blood tumor burden.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA